Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Adalimumab (1)
- Adolescent (1)
- Adrenal Cortex Hormones (1)
- Adult (1)
- Anti-Inflammatory Agents, Non-Steroidal (1)
-
- Anticoagulants (1)
- Antiviral Agents (1)
- Child (1)
- Congenital heart disease (1)
- Drug Interactions (1)
- Drug Resistance (1)
- Female (1)
- Galactose (1)
- Glomerular Filtration Rate (1)
- Glomerulosclerosis, Focal Segmental (1)
- Hypoplastic Left Heart Syndrome (1)
- Hypoplastic left heart syndrome (1)
- Immunosuppressive Agents (1)
- Influenza, Human (1)
- International Normalized Ratio (1)
- International normalized ratio (1)
- Oseltamivir (1)
- Proteinuria (1)
- Receptors, Urokinase Plasminogen Activator (1)
- Thrombosis (1)
- Warfarin (1)
- Young Adult (1)
Articles 1 - 2 of 2
Full-Text Articles in Pharmaceutical Preparations
Efficacy Of Galactose And Adalimumab In Patients With Resistant Focal Segmental Glomerulosclerosis: Report Of The Font Clinical Trial Group., Howard Trachtman, Suzanne Vento, Emily Herreshoff, Milena Radeva, Jennifer Gassman, Daniel T. Stein, Virginia J. Savin, Mukut Sharma, Jochen Reiser, Changli Wei, Michael Somers, Tarak Srivastava, Debbie S. Gipson
Efficacy Of Galactose And Adalimumab In Patients With Resistant Focal Segmental Glomerulosclerosis: Report Of The Font Clinical Trial Group., Howard Trachtman, Suzanne Vento, Emily Herreshoff, Milena Radeva, Jennifer Gassman, Daniel T. Stein, Virginia J. Savin, Mukut Sharma, Jochen Reiser, Changli Wei, Michael Somers, Tarak Srivastava, Debbie S. Gipson
Manuscripts, Articles, Book Chapters and Other Papers
BACKGROUND: Patients with resistant focal segmental glomerulosclerosis (FSGS) who are unresponsive to corticosteroids and other immunosuppressive agents are at very high risk of progression to end stage kidney disease. In the absence of curative treatment, current therapy centers on renoprotective interventions that reduce proteinuria and fibrosis. The FONT (Novel Therapies for Resistant FSGS) Phase II clinical trial (NCT00814255, Registration date December 22, 2008) was designed to assess the efficacy of adalimumab and galactose compared to standard medical therapy which was comprised of lisinopril, losartan, and atorvastatin.
METHODS: Key eligibility criteria were biopsy confirmed primary FSGS or documentation of a causative …
Oseltamivir-Warfarin Interaction In Hypoplastic Left Heart Syndrome: Case Report And Review., Jonathan B. Wagner, Susan M. Abdel-Rahman
Oseltamivir-Warfarin Interaction In Hypoplastic Left Heart Syndrome: Case Report And Review., Jonathan B. Wagner, Susan M. Abdel-Rahman
Manuscripts, Articles, Book Chapters and Other Papers
An 8-year-old boy with hypoplastic left heart syndrome with a previous history of thrombosis within the inferior vena cava receiving stable warfarin dosing for anticoagulation was diagnosed with influenza B. He was subsequently placed on oseltamivir therapy according to the Centers for Disease Control and Prevention clinical practice guidelines. During the hospitalization, his international normalized ratio steadily increased to supratherapeutic levels and returned to baseline after discontinuation of oseltamivir therapy. This case represents a drug-drug interaction that has not been previously reported in children or adolescents. An extensive review of the pharmacokinetic and pharmacodynamic literature did not uncover a definitive …